10 Results for "

oGTT

" in MedChemExpress (MCE) Product Catalog:
Products (10)

10 Results for "oGTT" in MCE Product Catalog:

Cat. No.: HY-119322
CAS No.: 279215-43-9
Purity:  ≥99.0%
Synonyms: NN414
Target:  

Potassium Channel

Research Areas:  

Metabolic Disease

Tifenazoxide (NN414) is a potent, orally active and SUR1/Kir6.2 selective K ATP channels opener. Tifenazoxide has antidiabetic effect, can inhibit glucose stimulated insulin release in vitro and in vivo, and has a beneficial effect on glucose homeostasis .
loading...
    loading...
Cat. No.: HY-102037
CAS No.: 1628741-91-2
Purity:  99.91%
Target:  

Somatostatin Receptor

Research Areas:  

Metabolic Disease Endocrinology

SSTR5 antagonist 1 (compound 25a) is a selective and orally available somatostatin receptor subtype 5 (SSTR5) antagonist with IC50s of 9.6 and 57 nM for hSSTR5 and mSSTR5, respectively .
loading...
    loading...
Cat. No.: HY-144289
CAS No.: 1001419-18-6
Purity:  99.75%
Target:  

Glucokinase

Research Areas:  

Metabolic Disease

BMS-820132 is an orally active and partial glucokinase (GK) activator with a AC50 of 29 nM. BMS-820132 decreases the glucose levels in glucose tolerance test (OGTT) model in normal rats, but not Zucker diabetic fatty (ZDF) rats. BMS-820132 exhibits pharmacological toxicity secondary to strong GK activation .
loading...
    loading...
Cat. No.: HY-119322R
CAS No.: 279215-43-9
Synonyms: NN414 (Standard)
Research Areas:  

Metabolic Disease

Tifenazoxide (Standard) is the analytical standard of Tifenazoxide. This product is intended for research and analytical applications. Tifenazoxide (NN414) is a potent, orally active and SUR1/Kir6.2 selective KATP channels opener. Tifenazoxide has antidiabetic effect, can inhibit glucose stimulated insulin release in vitro and in vivo, and has a beneficial effect on glucose homeostasis .
loading...
    loading...
Cat. No.: HY-173503
CAS No.: 1598439-44-1
Target:  

GLUT

Research Areas:  

Metabolic Disease

DS-1150b is an orally active GLUT4 activator. DS-1150b has the activity of activating GLUT4 transport and can promote the translocation of GLUT4 to the cell membrane in skeletal muscle cells. DS-1150b has shown hypoglycemic effects in the Zucker obese rat model and can be used in the study of type 2 diabetes mellitus (T2DM) .
loading...
    loading...
Cat. No.: HY-179419
Target:  

Glucokinase

Research Areas:  

Metabolic Disease

Glucokinase activator 10, a thiazole-based compound, is a liver-selective and orally active glucokinase activator with an EC50 of 42 nM. Glucokinase activator 10 exhibits significant glucose lowering in acute diet-induced obese mouse oral glucose tolerance (OGTT) test. Glucokinase activator 10 can be used for the study of metabolic disorders .
loading...
    loading...
Cat. No.: HY-102037R
CAS No.: 1628741-91-2
SSTR5 antagonist 1 (Standard) is the analytical standard of SSTR5 antagonist 1 (HY-102037). This product is intended for research and analytical applications. SSTR5 antagonist 1 (compound 25a) is a selective and orally available somatostatin receptor subtype 5 (SSTR5) antagonist with IC50s of 9.6 and 57 nM for hSSTR5 and mSSTR5, respectively .
loading...
    loading...
Cat. No.: HY-160156
CAS No.: 916338-03-9
Target:  

Somatostatin Receptor

Research Areas:  

Metabolic Disease

SSTR5 antagonist 4 (compound 1) is a potent, selective and orally active somatostatin subtype 5 (SSTR5) antagonist (hSSTR5 IC50 = 1.3 nM, mSSTR5 IC50 = 1.0 nM). SSTR5 antagonist 4 shows efficacy in mouse oral glucose tolerance test (OGTT) in high fat diet (HFD)-mice. SSTR5 antagonist 4 can be used for type 2 diabetes research .
loading...
    loading...
Cat. No.: HY-180527
Research Areas:  

Metabolic Disease

SGLT2-IN-5 (Compound 99) is an orally active SGLT2 inhibitor with IC₅₀ values for SGLT2, SGLT1, and DPP4 of 0.8, 23, and 58 nM respectively. SGLT2-IN-5 controls blood sugar levels in diabetic rat models and increases the levels of active GLP-1. SGLT2-IN-5 can be used for the study of type 2 diabetes .
loading...
    loading...
Cat. No.: HY-182729
CAS No.: 1229363-11-4
Research Areas:  

Metabolic Disease

FFA2 agonist-2 is a potent agonist of the FFA2 (GPR43) receptor, with a pEC50 of 7.9 for human FFA2, and a pEC50 of 7.3 for murine FFA2. FFA2 agonist-2 acts as an orthosteric agonist and shows no obvious cross‑activity against FFA1, FFA3 and FFA4. FFA2 agonist-2 can be used for FFA2 receptor research in type 2 diabetes and metabolic disorders .
loading...
    loading...